Astria Therapeutics Inc

Astria Therapeutics — Investor Presentation (January 2023)

19 slides from Astria Therapeutics's investor presentation, Jan 5, 2023

  1. Slide 1: Corporate Presentation January 2023

    Slide 1: Corporate Presentation January 2023

    Corporate Presentation January 2023 1 Confidential

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and various remarks we make during this presentation contain forward - looking statements of Astria Therapeutics, Inc .. (“Astria,” the “Company,” “we”, “our” or “us”) within the meaning of applicable securities laws and regulations, including statements

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights 3 Astria (Nasdaq: ATXS) is developing differentiated therapeutics for patients with rare and niche allergic and immunological diseases Our lead program, STAR - 0215 , is a monoclonal antibody inhibitor of plasma kallikrein for the preventative treatment of Hereditary Angioedema

  4. Slide 4: Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life-Threatening Disease

    Slide 4: Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life-Threatening Disease

    Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life - Threatening Disease 4 1. Zuraw BL. N Engl J Med. 2008;359:1027 - 36. 2. Busse, P.J. et al. N Engl J Med. 2021; 132 - 150. 3. Lumry , W.R. Front Med. 2018; 5, 22. 4. Aygören - Pürsün , E. et.al. Orphanet j Rare Dis. 2018; 13:73.

  5. Slide 5: Global HAE Treatment Market is Substantial and Growing

    Slide 5: Global HAE Treatment Market is Substantial and Growing

    Global HAE Treatment Market is Substantial and Growing 5 1. Company - reported sales (Takeda, CSL Behring, Pharming, BioCryst ) 2. Analyst consensus forecasts compiled by Clarivate’s Cortellis , Astria company research and analysis. 3. Zanichelli A. Clin Transl Allergy. 2018: doi : 10.1186/s13601 -

  6. Slide 6: Approved and Late-Stage Preventative HAE Treatments

    Slide 6: Approved and Late-Stage Preventative HAE Treatments

    Approved and Late - Stage Preventative HAE Treatments 6 *Efficacy quoted as reduction in mean attack rate vs placebo; data from respective products’ Prescribing Information 1,2,3,7 .. 1. CINRYZE Prescribing Information, 2021. 2. HAEGARDA Prescribing Information, 2020. 3. TAKHZYRO Prescribing Informa

  7. Slide 7: STAR-0215's Target Efficacy and Dosing is Compelling to Surveyed HAE Treatment Providers and Patients

    Slide 7: STAR-0215's Target Efficacy and Dosing is Compelling to Surveyed HAE Treatment Providers and Patients

    STAR - 0215’s Target Efficacy and Dosing is Compelling to Surveyed HAE Treatment Providers and Patients 7 Survey respondents were shown a blinded product profile that included: a monoclonal antibody inhibitor of plasma kallikrein t hat helps prevent HAE attacks by suppressing the pathway that genera

  8. Slide 8: Potential for Best-in-Class Profile in HAE

    Slide 8: Potential for Best-in-Class Profile in HAE

    STAR - 0215 Potential for Best - in - Class Profile in HAE 8 1. If this application is nationalized in PCT member states ex - U.S., the term of any resulting patents would also be to 2042, ex clusive of any available term extensions. Novel CDRs with patent pending Fc engineered with YTE modification

  9. Slide 9: Phase 1a Trial Design

    Slide 9: Phase 1a Trial Design

    STAR - 0215 Phase 1a Trial 9 • Randomized, double - blind 1 , placebo - controlled ▪ Healthy adult subjects ▪ 3 single ascending doses, delivered SC ▪ 6 active to 2 placebo randomization • Preliminary data include safety (84 days for 3 cohorts), PK and PD (84 days for cohorts 1 and 2; 56 days for co

  10. Slide 10: Phase 1a Safety Results

    Slide 10: Phase 1a Safety Results

    10 STAR - 0215 1 : • 8 (32%) subjects (STAR - 0215 or placebo) had related TEAEs • No SAEs and all related TEAEs were mild (Grade 1) and resolved. No Grade 2, 3, or 4 TEAEs. • 6 subjects had ISRs (all mild), most commonly site redness; no reports of pain TEAE= Treatment - emergent adverse event; ISR

  11. Slide 11: Results Show STAR-0215 has a Potential Best-In-Class PK Profile

    Slide 11: Results Show STAR-0215 has a Potential Best-In-Class PK Profile

    11 Results Show STAR - 0215 has a Potential Best - In - Class PK Profile Results will be finalized after the end of the observation period 1. Chyung et al 2014. Weight (SD) in this dose cohort = 83.08 (9.459) kg. Mean dose is 249.2 mg SC. The comparison presented between STAR - 0215 and lanadelumab

  12. Slide 12: Results Show Rapid and Sustained Concentrations After Single Subcutaneous Doses

    Slide 12: Results Show Rapid and Sustained Concentrations After Single Subcutaneous Doses

    Results Show Rapid and Sustained STAR - 0215 Concentrations After Single Subcutaneous Doses 12 Mean (SD) concentrations over time Results will be finalized after the end of the observation period STAR - 0215 : • Concentrations are proportional to dose • Long elimination phase consistent with YTE - m

  13. Slide 13: Modeling Supports Potential for Clinical Benefit with Infrequent Dosing

    Slide 13: Modeling Supports Potential for Clinical Benefit with Infrequent Dosing

    Modeling Supports Potential for Clinical Benefit with Infrequent Dosing 13 1. Kaufman 1991 June 15. Blood 77(12): 2660 - 2667 2. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi 10 - 1111/ cts .. 12806 Epub 2020 May 26. 3. Ecallantide EMA Assessment Report. 2011 June 23. EMA/CHMP/47661

  14. Slide 14: Target Engagement is Assessed by Change in FXIIa-Activated cHMWK

    Slide 14: Target Engagement is Assessed by Change in FXIIa-Activated cHMWK

    Target Engagement is Assessed by Change in FXIIa - Activated cHMWK 14 *p = 0.001; **p = 0.003 HMWK = high molecular weight kininogen cHMWK = cleaved high molecular weight kininogen FXIIa = activated Factor XII PLASMA KALLIKREIN INHIBITION BY STAR - 0215 Bradykinin MEASURED BY PD ASSAY cHMWK + HMWK F

  15. Slide 15: Results Show STAR-0215 Achieves Sustained Inhibition of Plasma Kallikrein

    Slide 15: Results Show STAR-0215 Achieves Sustained Inhibition of Plasma Kallikrein

    Results Show STAR - 0215 Achieves Sustained Inhibition of Plasma Kallikrein 15 No significant changes at any timepoints with placebo or 100 mg STAR - 0215 Results will be finalized after the end of the observation period 1. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi 10 - 1111/ ct

  16. Slide 16: Proposed ALPHA-STAR Trial Design

    Slide 16: Proposed ALPHA-STAR Trial Design

    1. This cohort is expected to commence after a safety assessment of Cohort 1 Proposed ALPHA - STAR Trial Design Open - Label Single and Multiple Dose Phase 1b/2 POC Clinical Trial in HAE Single Dose, n =4 8 - week Run - In Planned Phase 2 Long - Term Open - Label Trial (LTOL) 450 mg, 6 - month follo

  17. Slide 17: Overview of the Expected Clinical Development Plan

    Slide 17: Overview of the Expected Clinical Development Plan

    Overview of the Expected Clinical Development Plan Long - Term Open Label Trial Phase 3 Pivotal Trial in HAE Patients Initial results Q4 ‘23 Phase 1a, SAD - Healthy Subjects Initial results Mid ‘24 New cohorts Q1 ‘23 Initiate Q1 ‘23 Initiate H2 ‘23 ALPHA - STAR Phase 1b/2 POC Trial - HAE Patients PH

  18. Slide 18: Well-Positioned for the Future: Expected Upcoming Milestones

    Slide 18: Well-Positioned for the Future: Expected Upcoming Milestones

    18 1. As of 12/31/2022, unaudited and preliminary 2. As of 12/30/2022 2023 2024 PHASE 1A • Phase 1a 3 - month results at scientific conference • Initiate additional Phase 1a cohorts to evaluate 6 - month dosing PHASE 1B/2 Q1 • Phase 1b/2 ALPHA - STAR trial initiation PHASE 1A Q4 Preliminary results

  19. Slide 19

    Slide 19

Source: SEC EDGAR · 8-K filed Jan 5, 2023

More decks from Astria Therapeutics Inc